Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition

Shi-Yong Sun, Laura M. Rosenberg, Xuerong Wang, Zhongmei Zhou, Ping Yue, Haian Fu, and Fadlo R. Khuri

Department of Hematology and Oncology and Winship Cancer Institute and Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia

Abstract

The mammalian target of rapamycin (mTOR) has emerged as an important cancer therapeutic target. Rapamycin and its derivatives that specifically inhibit mTOR are now being actively evaluated in clinical trials. Recently, the inhibition of mTOR has been shown to reverse Akt-dependent prostate intraepithelial neoplasia. However, many cancer cells are resistant to rapamycin and its derivatives. The mechanism of this resistance remains a subject of major therapeutic significance. Here we report that the inhibition of mTOR by rapamycin triggers the activation of two survival signaling pathways that may contribute to drug resistance. Treatment of human lung cancer cells with rapamycin suppressed the phosphorylation of p70S6 kinase and 4E-BP1, indicating an inhibition of mTOR signaling. Paradoxically, rapamycin also concurrently increased the phosphorylation of both Akt and eIF4E. The rapamycin-induced phosphorylation of Akt and eIF4E was suppressed by the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002, suggesting the requirement of PI3K in this process. The activated Akt and eIF4E seem to attenuate rapamycin’s growth-inhibitory effects, serving as a negative feedback mechanism. In support of this model, rapamycin combined with LY294002 exhibited enhanced inhibitory effects on the growth and colony formation of cancer cells. Thus, our study provides a mechanistic basis for enhancing mTOR-targeted cancer therapy by combining an mTOR inhibitor with a PI3K or Akt inhibitor. (Cancer Res 2005; 65(16): 7052-8)

Introduction

The mammalian target of rapamycin (mTOR), a 289-kDa serine/threonine kinase, belongs to the phosphatidylinositol kinase-related kinase family. It plays a central role in regulating cell growth, proliferation, and survival, in part by regulation of translation initiation (1–3). In response to mitogen stimulation, mTOR regulates translation initiation through two distinct pathways: ribosomal p70 S6 kinase (p70S6K) and eukaryotic translation initiation factor 4E (eIF4E) binding proteins (4E-BPs). In one pathway, mTOR phosphorylates and activates p70S6K, which in turn phosphorylates the 40S ribosomal protein S6, leading to the enhancement of translation of mRNAs with a 5’-terminal oligopyrimidine, including mRNAs that encode for ribosomal proteins and elongation factor-1. In another pathway, mTOR directly phosphorylates 4E-BP1, causing its dissociation from eIF4E, thereby increasing the availability of functional eIF4E, a rate-limiting component for cap-dependent translation. The free eIF4E then binds to eIF4G, promoting the assembly of the eIF4F initiation complex, which then leads to more efficient cap-dependent translation initiation, increasing the translation of mRNAs with long, highly structured 5’-untranslated regions, such as cyclin D1 and c-Myc (1–3).

The phosphatidylinositol-3 kinase (PI3K)/Akt signaling represents a major cell survival pathway. Its activation has long been associated with malignant transformation and apoptotic resistance (4). It has been well documented that mTOR functions downstream of the PI3K/Akt pathway and is phosphorylated (or activated) in response to stimuli that activate the PI3K/Akt pathway (1, 3). Normally, the phosphatase PTEN counters the PI3K activity and thus negatively regulates PI3K/Akt survival pathway. However, PTEN activity is frequently inactivated in many human tumor types through deletion, mutation, or silencing, leading to increased activation of Akt (4, 5). Additional mechanisms have also been found to induce the activation of the PI3K/Akt pathway, including oncogene (e.g., Ras) amplification and mutations, active mutations in the p110 and p85 subunits of PI3K, and Akt overexpression. Thus, mTOR signaling pathways are constitutively activated in many types of human cancer (1, 6). Recent studies have shown that the mutation of tuberous sclerosis complex and overexpression of Rheb that work downstream of Akt in regulating the mTOR signaling also occur in human cancers, contributing to mTOR activation (7). Moreover, eIF4E is overexpressed or amplified in many human cancers, which is often oncogenic (1, 6, 8). Therefore, mTOR signaling has emerged as an important and attractive therapeutic target for cancer therapy (1, 2). The potential applications of mTOR inhibitors for treating various types of cancer have been actively studied both preclinically and clinically. A recent animal study has shown that mTOR inhibition induces apoptosis of epithelial cells and reverses Akt-dependent prostate intraepithelial neoplasia (9). In the United States, several phase II or III trials are ongoing to test the effects of mTOR inhibitors on various cancers, including renal cell carcinoma, prostate, breast, pancreatic, and small cell lung cancers, recurrent brain tumors, recurrent mantle-cell lymphoma, and melanoma (1, 10).

The intrinsic sensitivity to mTOR inhibition by rapamycin among different cancer cell lines may vary by several orders of magnitude ranging from 1 to 5,000 nmol/L (IC_{50}; ref. 11), indicating that some cancer cell lines are actually resistant to mTOR inhibition. Therefore, understanding the mechanisms by which cells become resistant to mTOR inhibitors may guide the development of successful mTOR-targeted cancer therapy. Using

Requests for reprints: Shi-Yong Sun, Winship Cancer Institute, Emory University School of Medicine, 1365-C Clifton Road, C3088, Atlanta, GA 30322. Phone: 404-778-2170; Fax: 404-778-5520; E-mail: shi-yong.sun@emoryhealthcare.org. ©2005 American Association for Cancer Research. doi:10.1158/0008-5472.CAN-05-0917


Downloaded from cancerres.aacrjournals.org on April 14, 2017. © 2005 American Association for Cancer Research.
human non–small cell lung cancer (NSCLC) cells, here we report that mTOR inhibition by rapamycin induces activation of survival pathways involving increase of Akt and eIF4E phosphorylation. We show that prevention or disruption of the activation of Akt and eIF4E enhanced rapamycin-mediated growth inhibition, indicating that the induced activation of Akt and eIF4E survival pathways counteracts the mTOR inhibitor’s effect on the growth of human cancer cells.

Materials and Methods

Reagents. Rapamycin was purchased from LKT Laboratories, Inc. (St. Paul, MN). LY294002 and U0126 were purchased from LC Laboratories (Woburn, MA). PD98059 and SB203580 were purchased from Biomol (Plymouth Meeting, PA) and Calbiochem (San Diego, CA), respectively. These agents were dissolved in DMSO at a concentration of 10 or 20 mmol/L, and aliquots were stored at −80°C. Stock solutions were diluted to the desired final concentrations with growth medium just before use. Rabbit polyclonal antibodies against Akt, mTOR, p70S6K, eIF4E, phospho-Akt (p-Akt, Ser473), phospho-mTOR (p-mTOR, Ser2448), phospho-GSK3β (p-GSK3β, Ser9), phospho-p70S6K (p-p70S6K, Thr389), phospho-4E-BP1 (p-4E-BP1, Thr37/46), antibodies and then antibody binding was detected using the SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology, Inc., Rockford, IL) according to the manufacturer’s protocol.

Colony formation assay. Cells (single-cell suspension) were plated in 96-well culture plates and treated on the second day with rapamycin, LY294002, or rapamycin combined with LY294002. At the end of a 3-day treatment, cell number was estimated by the sulforhodamine B (SRB) assay as previously described (12). The percentage of growth inhibition was calculated by using the equation:

\[
\text{growth inhibition} = \left(1 - \frac{A_c}{A_t}\right) \times 100, \quad \text{where} \ A_t \text{ and} A_c \text{ represent the absorbance in treated and control cultures, respectively.}
\]

Results

Inhibition of mammalian target of rapamycin by rapamycin increases the phosphorylation of Akt and eIF4E. To evaluate the effects of rapamycin on the status of molecules proximal to the mTOR axis, we probed the phosphorylation states of Akt and eIF4E. Because Akt has been placed upstream of mTOR in many cell types, we speculated that rapamycin would not alter the phosphorylation levels of Akt (p-Akt). Unexpectedly, all of the

[Graph: Figure 1. Effects of rapamycin on the growth of human NSCLC cells. The indicated cell lines were plated in 96-well plates and treated on the second day with the indicated concentrations of rapamycin. After 3 days, plates were subjected to determination of cell number using a SRB assay. Points, means of four replicate determinations; bars, ±SD.]
tested cell lines exposed to rapamycin exhibited increased p-Akt at Ser473, indicative of an activated Akt in these cells (Fig. 2B). In support of this notion, in response to rapamycin treatment, GSK3β, a well-established physiologic substrate of Akt, is also phosphorylated in these cells at Ser9, a defined Akt phosphorylation site. These data suggest that rapamycin-induced mTOR inhibition results in the activation of the Akt survival pathway. In addition to Akt, the treatment of NSCLC cells with rapamycin also induced the phosphorylation of eIF4E (p-eIF4E), a molecule downstream of mTOR that is involved in promoting cell survival (8, 14). Phosphorylation of eIF4E may counteract the mTOR inhibition effect, leading to a decreased growth-inhibitory effect of rapamycin. Together, these results suggest that rapamycin-induced suppression of mTOR signaling and increased phosphorylation of Akt and eIF4E is a common event in cancer cells.

To further explore the relationship between the suppression of mTOR signaling and the increased phosphorylation of Akt and eIF4E, we examined the effects of rapamycin on the expression levels of p70S6K, Akt, and eIF4E in cells treated with different concentrations of rapamycin ranging from 0.01 to 10 nmol/L. Rapamycin at 0.01 and 0.1 nmol/L failed to alter the phosphorylation levels of either protein. However, in cells treated with 1 or 10 nmol/L rapamycin, p-p70S6K levels decreased, accompanied with increases of both p-Akt and p-eIF4E levels (Fig. 3C). These findings indicate a close relationship between the suppression of mTOR signaling and the activation of Akt and eIF4E.

Phosphatidylinositol 3-kinase is required for rapamycin-induced phosphorylation of Akt and eIF4E. To understand the mechanism by which rapamycin induces Akt activation, we investigated the involvement of PI3K, an upstream regulator of Akt, in this process. PI3K catalyzes the production of the lipid second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3)
at the cell membrane. PIP3 in turn recruits other pleckstrin homology domain–containing proteins, in particular Akt, to the membrane, where Akt is activated by PDK1 and a Ser473 kinase (4). If PI3K is involved in Akt activation induced by mTOR inhibition, the PI3K inhibitor LY294002 would block or suppress the Akt phosphorylation or activation by rapamycin. Therefore, we examined the effects of LY294002 on rapamycin-induced Akt activation and eIF4E phosphorylation. In the absence of LY294002, rapamycin at both 1 and 10 nmol/L increased p-Akt and p-GSK3β levels. In the presence of LY294002, rapamycin failed to increase Akt and GSK3β phosphorylation (Fig. 4A). These results suggest that rapamycin-induced Akt activation requires activated PI3K. Similarly, LY294002 also blocked the rapamycin-induced increase of eIF4E phosphorylation (Fig. 4A), suggesting that the rapamycin-induced increase of p-eIF4E is dependent on PI3K activation as well.

Both mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) and p38 MAPK are known to regulate eIF4E phosphorylation through Mnk1 (15, 16). To determine whether MEK/ERK or the p38 MAPK pathway was involved in the rapamycin-mediated increase of p-eIF4E, we analyzed the p-eIF4E levels in cells treated with rapamycin. These inhibitors include the MEK inhibitors U0126 and PD98059, the p38 MAPK inhibitor SB203580, and the PI3K inhibitor LY294002. As shown in Fig. 4B, the presence of U0129, PD98059, or SB203580 neither affected the rapamycin-induced increase of p-eIF4E and p-Akt, nor the decrease of p-p70S6K by rapamycin. Rapamycin did not increase p-p44/p42 levels at the time point tested, whereas both U0126 and PD98059 decreased basal levels of p-p44/p42, indicating that they indeed function to block MEK/ERK pathway. p38 MAPK levels were undetectable under the conditions tested (data not shown). These results suggest that either the MEK/ERK or the p38 MAPK pathway is unlikely involved in mediating the rapamycin-induced increase of p-eIF4E. As we have already shown, LY294002 did not block the rapamycin-mediated decrease of p-p70S6K but abrogated rapamycin-induced increases of both p-Akt and p-eIF4E. Thus, it seems that the rapamycin-induced increase of p-eIF4E is PI3K dependent but independent of the MEK/ERK and p38 MAPK pathway.

Combination of rapamycin with LY294002 exhibits enhanced inhibitory effects on the growth and colony formation of non–small cell lung cancer cells. It is well documented that Akt is a major survival kinase (4). Recently, eIF4E has also been shown to be a tumor survival factor (8, 14). Our data clearly show that suppression of mTOR by rapamycin activates Akt and eIF4E survival pathways. Thus, we speculated that PI3K/Akt and eIF4E activation would counteract mTOR inhibitors’ anticancer effects. Because rapamycin-induced Akt activation requires its upstream regulator, PI3K (Fig. 4A and B), blocking the PI3K/Akt survival pathway by LY294002 would be expected to enhance the rapamycin effect. Thus, we examined the effects of rapamycin combined with LY294002 on the growth of human NSCLC cells. As shown in Fig. 4C, the combination of rapamycin and LY294002 in a 3-day growth inhibition assay apparently exhibit growth-inhibitory effects that are greater than those caused by each single agent alone. For example, in H157 cells, rapamycin at 1 nmol/L inhibited cell growth by 30%, whereas LY294002 at 0.5, 1.0, 2.5, and 5.0 μmol/L caused 4.6%, 3.2%, 11%, and 17.9% growth inhibition, respectively. However, their combinations led to growth inhibition by 46.5%.

Figure 3. Increase of Akt and eIF4E phosphorylation by rapamycin is associated with suppression of the mTOR signaling in human NSCLC cells. The indicated cells lines were treated with 100 nmol/L rapamycin (Rap) for the given times (A and B) or with the indicated concentrations of rapamycin for 24 hours (C) and then subjected to preparation of whole cell protein lysates. The indicated proteins were detected by Western blot analysis.
52.2%, 58.9%, and 67.3%, respectively. These effects are apparently greater than the sum of the inhibitory effects caused by each agent alone, indicating a more than additive or synergistic effect. In the long-term colony formation assay, we obtained similar results as determined from the 3-day assay. LY294002 and rapamycin alone did not decrease the number of colonies, although they reduced the sizes of the colonies. The combination of the two agents not only decreased the size of colonies but also reduced the number of colonies (Fig. 4D), indicating that the combination causes a greater growth-inhibitory effect than that of each single agent. Taken together, these results indicate that the combination of rapamycin and LY294002 results in an augmented growth-inhibitory effect.

Discussion

Using several human NSCLC cell lines, we have shown that rapamycin effectively inhibits cell growth to various degrees. However, rapamycin failed to completely inhibit cell growth even when its concentration was increased up to 10 μmol/L, suggesting that some cells remain resistant to mTOR inhibitors. Cell sensitivity to mTOR inhibitors has been linked to PTEN mutations or Akt activation (17–20). PTEN is a PIP3 phosphatase that negatively regulates the PI3K/Akt pathway. A recent animal study has shown that mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia (9). It has been well documented that human NSCLCs have rare or low frequencies of PTEN mutations (21, 22). Among tested NSCLC cell lines, H157 is the only cell line with PTEN mutation (21). Compared with most NSCLC cell lines, which have very low or undetectable basal levels of p-Akt, H157 cells constitutively express high levels of p-Akt, as we have shown previously (23). However, H157 cells were not more sensitive than other cell lines, such as A549 and H460, to rapamycin. Therefore, the effect of PTEN mutations or Akt activation on rapamycin’s effects in NSCLC cells is not clearly apparent in NSCLC cells.
Rapamycin at concentrations (≥1 nmol/L) that exhibited growth inhibition rapidly and effectively suppressed the phosphorylation of p70S6K and 4E-BP1, indicating that rapamycin indeed blocks mTOR signaling. This blockage may well be the molecular basis for rapamycin to inhibit the growth of cancer cells. Unexpectedly, rapamycin rapidly induced the activation of Akt as shown by phosphorylation at Ser473 and the phosphorylation of its substrate, GSK3β, whereas suppressing the phosphorylation of p70S6K and 4E-BP1. It seems that mTOR inhibition by rapamycin activates the Akt survival pathway. Even more surprisingly, cells treated with rapamycin within a concentration range that inhibits mTOR signaling increased eIF4E phosphorylation. To our knowledge, this is the first report to show that mTOR inhibition by rapamycin increases eIF4E phosphorylation.

Activation of Akt by mTOR inhibition was reported in Drosophila when studying the functional role of Rheb in regulation of p70S6K activity (24) and also in mammalian skeletal muscle cells, adipocytes, and fibroblasts when studying insulin signaling (25–27). Our study clearly shows that mTOR inhibition by rapamycin results in the activation of the Akt survival pathway in human NSCLC and other types of cancer cell lines. To the best of our knowledge, this is the first report to show mTOR inhibition–induced Akt activation in human cancer cells. Results from previous studies of insulin signaling suggest that the mTOR activation by insulin initiates a feedback inhibition of PI3K/Akt through p70S6K activation and its subsequent phosphorylation of insulin receptor substrate-1 (IRS-1). The phosphorylation of IRS-1 promotes IRS-1 degradation and reduces IRS-1 expression, leading to decreased activity of PI3K/Akt. Rapamycin suppresses p70S6K and thus relieves this negative feedback inhibition of Akt (28, 29). In our study, the presence of the PI3K inhibitor, LY294002, abrogated rapamycin-induced Akt activation (Akt and GSK3β phosphorylation), suggesting that PI3K activity is required for Akt activation by rapamycin. However, we currently do not know whether the Akt activation induced by rapamycin in human cancer cells is mediated by p70S6K suppression through the stabilization of IRS-1. It has been shown that there are two mTOR complexes in mammalian cells: the rapamycin-sensitive mTOR-raptor complex and the rapamycin-insensitive mTOR-rictor complex (30). A recent study has shown that the mTOR-rictor complex can directly phosphorylate Akt at Ser473 (31). Reduction of mTOR expression using small interfering RNA decreased Akt phosphorylation (31). Our data seem to favor the model that rapamycin induces Akt phosphorylation in a PI3K-dependent mechanism. However, it remains possible that rapamycin may indirectly stimulate the mTOR-rictor kinase activity to phosphorylate Akt. Elucidation of these mechanisms requires further investigation.

eIF4E plays a critical role in the regulation of cap-dependent-protein translation and thus its activity is integral in determining global translation rates (32). Consistent with this role, eIF4E is required for cell cycle progression, exhibits antiapoptotic or survival activity, and when overexpressed, transforms cells (8, 14), largely due to its critical role in initiating translation of mRNAs that encode cell cycle regulators or oncogenic proteins such as cyclin D1, ornithine decarboxylase, c-Myc, hypoxia-inducible factor 1α, fibroblast growth factor, and vascular endothelial growth factor (1, 8, 24). Therefore, it is not surprising that elevated levels of eIF4E are found in a broad spectrum of transformed cells and human cancers, including lung cancers, and is often associated with aggressive, poorly differentiated tumors (1, 8). eIF4E is phosphorylated (usually at Ser209) in many systems in response to extracellular stimuli including growth factors, hormones, and mitogens (15, 16). Its phosphorylation increases its affinity for the cap and for mRNA and may also favor its entry into initiation complexes (15, 16, 33). Although mTOR inhibitors are expected to inhibit cap-dependent translation via activation of 4E-BP1 (i.e., promoting its dephosphorylation), we paradoxically found that cells treated with rapamycin exhibited increased eIF4E phosphorylation. Thus, it seems that rapamycin treatment generates conflicting signal to cap-dependent protein translation. Collectively, these findings suggest that rapamycin may promote cap-dependent protein translation, probably under certain conditions.

It has been documented that MEK/ERK and p38 MAPK signaling pathways activate eIF4E through Mnk1-mediated phosphorylation of eIF4E (15, 16). However, the MEK inhibitors U0126 and PD98059 or the p38 MAPK inhibitor SB203580 did not inhibit a rapamycin-induced elevation of p-eIF4E. Instead, LY294002 abolished the increase of p-eIF4E by rapamycin. Thus, it seems that the PI3K activity is required for mediating rapamycin-induced eIF4E phosphorylation. The investigation on the involvement of Mnk1 in rapamycin-induced eIF4E phosphorylation is ongoing.

Because Akt and eIF4E are often associated with cell survival and resistance to cancer therapy (4, 14), our findings imply that the activation of Akt and eIF4E through mTOR inhibition may counteract mTOR inhibitors’ anticancer efficacy and confers resistance to mTOR-targeted cancer therapy. According to our results, Akt and eIF4E phosphorylation induced by rapamycin all occur downstream of PI3K. These findings may provide us the opportunity to interrupt or disrupt activation of the Akt and eIF4E survival pathways using a PI3K inhibitor or even an Akt inhibitor to enhance mTOR inhibitors’ anticancer efficacy or mTOR-targeted cancer therapy. Our results indeed show that LY294002 in combination with rapamycin exhibits enhanced (synergistic) effects on the growth and colony formation of human NSCLC cells. Therefore, from a therapeutic point of view, our findings suggest a novel strategy to enhance mTOR-targeted cancer therapy through combining an mTOR inhibitor with an inhibitor of the PI3K/Akt pathway.

Acknowledgments

Received 3/18/2005; revised 5/16/2005; accepted 6/16/2005.
Grant support: Winship Cancer Institute faculty start-up research fund (S-Y. Sun), the Georgia Cancer Coalition Distinguished Cancer Scholar award (S-Y. Sun and F.R. Khuri), Department of Defense IMPACT grant W81XWH-05-0027 (Project 5 to F.R. Khuri and S-Y. Sun), and NIH R01 grant GM53165 (H. Fu).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References

7. Inoki K, Corradetti MN, Guan KL. Dysregulation of the
Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition

Shi-Yong Sun, Laura M. Rosenberg, Xuerong Wang, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/65/16/7052

Cited articles
This article cites 33 articles, 12 of which you can access for free at:
http://cancerres.aacrjournals.org/content/65/16/7052.full.html#ref-list-1

Citing articles
This article has been cited by 100 HighWire-hosted articles. Access the articles at:
/content/65/16/7052.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.